TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Holdings Lowered by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company cut its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 4.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 75,327 shares of the biopharmaceutical company’s stock after selling 3,864 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in TG Therapeutics were worth $2,267,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Quadrant Capital Group LLC raised its holdings in shares of TG Therapeutics by 137.1% during the fourth quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 975 shares during the last quarter. Blue Trust Inc. boosted its position in TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 371 shares during the period. Smartleaf Asset Management LLC grew its stake in shares of TG Therapeutics by 512.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 1,594 shares in the last quarter. Jones Financial Companies Lllp grew its stake in shares of TG Therapeutics by 460.7% in the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company’s stock worth $64,000 after purchasing an additional 1,737 shares in the last quarter. Finally, Synergy Asset Management LLC acquired a new position in shares of TG Therapeutics during the fourth quarter valued at $75,000. 58.58% of the stock is owned by institutional investors and hedge funds.

TG Therapeutics Stock Performance

NASDAQ:TGTX opened at $33.64 on Friday. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The company has a 50-day moving average of $38.90 and a 200-day moving average of $33.63. TG Therapeutics, Inc. has a twelve month low of $15.16 and a twelve month high of $46.48. The firm has a market cap of $5.34 billion, a price-to-earnings ratio of -336.37 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.16). The business had revenue of $120.86 million during the quarter, compared to analyst estimates of $117.07 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company’s quarterly revenue was up 90.4% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.07) EPS. Analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

TGTX has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a research report on Tuesday, March 4th. StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $40.80.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.